Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
The pipeline is advancing with innovative immunotherapies and targeted treatment strategies. Cutaneous squamous cell carcinoma accounts for approximately 20% of all non-melanoma skin cancers, with an estimated 2%-5% of cases progressing to metastatic disease. Metastatic cutaneous squamous cell cancer pipeline analysis by Expert Market Research highlights increasing clinical investment in monoclonal antibodies, cell therapies, and novel small molecules to improve durable responses and long-term survival for patients with advanced disease.
-
Major companies involved in the metastatic cutaneous squamous cell cancer pipeline analysis include Merck Sharp & Dohme LLC, Hummingbird Bioscience, and others.
-
Leading drugs currently in the pipeline include 177Lu-RAD204 and others.
-
Rising incidence of advanced cutaneous squamous cell carcinoma, increasing demand for effective immunotherapies, advances in targeted and cell therapies, and expanding clinical research collaborations are driving the metastatic cutaneous squamous cell cancer pipeline.
Report Coverage
The Metastatic Cutaneous Squamous Cell Cancer Pipeline Analysis Report by Expert Market Research gives comprehensive insights into metastatic cutaneous squamous cell cancer therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for metastatic cutaneous squamous cell cancer. The metastatic cutaneous squamous cell cancer report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The metastatic cutaneous squamous cell cancer pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with metastatic cutaneous squamous cell cancer treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to metastatic cutaneous squamous cell cancer.
Read more about this report - Request a Free Sample
Metastatic Cutaneous Squamous Cell Cancer Pipeline Outlook
Metastatic cutaneous squamous cell cancer pipeline activity is being shaped by checkpoint inhibitor delivery improvements and patient-friendly treatment models. In September 2025, the FDA approved Keytruda Qlex, Merck’s subcutaneous pembrolizumab and berahyaluronidase alfa-pmph, for IV Keytruda’s approved solid tumor indications, including recurrent or metastatic cutaneous squamous cell carcinoma. This approval supports a shift from infusion-only care toward flexible administration in eligible patients. Future development is expected to focus on PD-1/PD-L1 combinations, longer dosing intervals, easier clinic use, and options for patients who relapse after current immunotherapy treatment in practice.
Metastatic Cutaneous Squamous Cell Cancer Epidemiology
Metastatic cutaneous squamous cell cancer remains a small but clinically important subset of cSCC. In the United States, basal and squamous cell skin cancers are not routinely captured by central cancer registries, which limits exact metastatic incidence tracking. CDC’s 2026 update notes that about 6.1 million adults are treated annually for basal and squamous cell cancers. The incidence of cSCC is rising, but metastasis occurs in only about 2% of cases. Risk is higher in older, immunosuppressed patients and tumors with high-risk clinicopathologic features.
Metastatic Cutaneous Squamous Cell Cancer – Pipeline Therapeutic Assessment
This section of the report covers the analysis of metastatic cutaneous squamous cell cancer drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
The metastatic cutaneous squamous cell cancer pipeline analysis report covers 50+ drug analyses based on drug classes:
- Small Molecules
- Oligonucleotides
- Peptides
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration:
- Oral
- Parenteral
- Others
Metastatic Cutaneous Squamous Cell Cancer Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total metastatic cutaneous squamous cell cancer clinical trials. Early phase 1 (3.23%), phase 1 (41.94%), phase 2 (45.16%), phase 3 (9.68).This distribution highlights a strong focus on early- and mid-stage clinical development, reflecting continued efforts to advance innovative therapies for metastatic cutaneous squamous cell cancer toward late-stage evaluation and potential commercialization.
Metastatic Cutaneous Squamous Cell Cancer Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the metastatic cutaneous squamous cell cancer pipeline analysis include small molecules, oligonucleotides and peptides. The metastatic cutaneous squamous cell cancer report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for metastatic cutaneous squamous cell cancer. In December 2024, FDA approved Unloxcyt for adults with metastatic cutaneous squamous cell carcinoma or locally advanced CSCC who are not candidates for curative surgery or curative radiation. It is a PD-L1 blocking antibody.
Metastatic Cutaneous Squamous Cell Cancer Clinical Trials – Key Players
The EMR report for the metastatic cutaneous squamous cell cancer pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed metastatic cutaneous squamous cell cancer therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in metastatic cutaneous squamous cell cancer clinical trials:
- InduPro, Inc.
- Incyte Corporation
- Merck Sharp & Dohme LLC
- Hummingbird Bioscience
- Ankyra Therapeutics, Inc.
- Onchilles Pharma Inc.
- Radiopharm Theranostics Ltd.
- Memgen, Inc.
- Iovance Biotherapeutics, Inc.
Metastatic Cutaneous Squamous Cell Cancer – Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for metastatic cutaneous squamous cell cancer. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of metastatic cutaneous squamous cell cancer drug candidates.
Drug: INCB099280
INCB099280 is an investigational small-molecule immunomodulatory therapy being developed by Incyte Corporation for advanced solid tumors, including metastatic cutaneous squamous cell carcinoma (cSCC). The candidate is designed to modulate the tumor microenvironment and enhance antitumor immune responses, potentially improving the effectiveness of immune-mediated cancer treatment. The ongoing clinical study is expected to be completed in 2028. Incyte Corporation is a global biopharmaceutical company recognized for developing innovative oncology and immunology therapies, with a strong portfolio of targeted and immune-based treatments.
Drug: IDP-001
IDP-001 is an investigational small-molecule therapeutic being developed by InduPro, Inc. for the treatment of metastatic cutaneous squamous cell carcinoma and other solid tumors. It is designed to target disease-associated proteins involved in tumor growth and survival, disrupting key oncogenic signaling pathways while promoting antitumor activity. The ongoing early-stage clinical trial is expected to reach completion in 2027. InduPro, Inc. is a biotechnology company specializing in precision protein-targeting technologies to develop first-in-class therapeutics for difficult-to-treat cancers.
Biological: N17350
N17350 is an investigational biological therapy being developed by Hummingbird Bioscience for patients with metastatic cutaneous squamous cell carcinoma and other advanced malignancies. As a biologic, it is engineered to selectively engage immune pathways that enhance T-cell-mediated antitumor responses while limiting immune suppression within the tumor microenvironment. The current clinical program is expected to be completed in 2028. Hummingbird Bioscience is a clinical-stage biotechnology company focused on developing precision antibody therapeutics targeting validated and novel cancer pathways.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
Key Questions Answered in the Metastatic Cutaneous Squamous Cell Cancer Pipeline Insight Report
- Which companies/institutions are leading the metastatic cutaneous squamous cell cancer drug development?
- Which company is leading the metastatic cutaneous squamous cell cancer pipeline development activities?
- What is the current metastatic cutaneous squamous cell cancer commercial assessment?
- What are the opportunities and challenges present in the metastatic cutaneous squamous cell cancer pipeline landscape?
- What is the efficacy and safety profile of metastatic cutaneous squamous cell cancer pipeline drugs?
- Which company is conducting major trials for metastatic cutaneous squamous cell cancer drugs?
- Which companies/institutions are involved in metastatic cutaneous squamous cell cancer collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in metastatic cutaneous squamous cell cancer?
Reasons To Buy This Report
The Metastatic Cutaneous Squamous Cell Cancer Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for metastatic cutaneous squamous cell cancer. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into metastatic cutaneous squamous cell cancer collaborations, regulatory environments, and potential growth opportunities.
Related Reports
Recurrent Head and Neck Cancer Squamous Cell Carcinoma Market
Recurrent Head and Neck Cancer Squamous Cell Carcinoma Pipeline Analysis Report
Pricing Plans
Upto 15% Off
USD
-
$1999 $1799
-
$3099 $2789
-
$4599 $3909
-
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
